CXCL10 anticorps (Biotin)

N° du produit ABIN2661156

Cet anticorps Chèvre Polyclonal détecte spécifiquement CXCL10 dans FACS. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour CXCL10 anticorps (Biotin) (ABIN2661156)

Antigène: CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))

Reactivité: Humain

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp CXCL10 est conjugé à/à la Biotin

Application: Flow Cytometry (FACS)

Clone: Poly5194

Détail du produit anti-CXCL10 anticorps (Biotin)

Purification: The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur CXCL10

Antigène: CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))

Autre désignation: CXCL10

Sujet: CXCL10 is an ELR-negative chemokine structurally and functionally related to CXCL9 and CXCL11. CXCL10, CXCL9, and CXCL11 are produced and secreted by monocytes, macrophages, fibroblasts, and epithelial cells upon stimulation with proinflammatory cytokines, especially IFNγ. CXCL10 chemoattracts CD4, CD8, and NK and NKT cells through the binding to its receptor CXCR3, which is shared with CXCL9 and CXCL11. In addition, CXCL10 inhibits neovascularization in tumors and in wound healing in vivo. Also, CXCL10 has anti-proliferative effects on endothelial cells in vitro, and angiostatic and antitumor effects in vivo. It has been suggested that the anti-proliferative effect of CXCL10 in endothelial cells is CXCR3-independent and that it is mediated through GAG interaction. CXCL10 also possesses antimicrobial activity against E. coli and L. monocytogenes, and both the spore and bacillus forms of B. anthracis. CXCL10 expression is strongly upregulated in many human inflammatory diseases, including rheumatoid arthritis, type I diabetes, multiple sclerosis, atherosclerosis, allograft rejection, and others.